Who may be eligible for the Biofluid Research on Age-Related or Inherited Neurodegeneration trial?

Inclusion Criteria: 1. People with a clinical diagnosis of a neurodegenerative disease including, but not limited to Alzheimer's disease (AD), Parkinson's disease (PD), Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP), primary progressive aphasia (PPA), limbic-predominant age-related TDP-43 encephalopathy (LATE), corticobasal syndrome (CBS), posterior cortical atrophy (PCA), primary lateral sclerosis (PLS), primary muscular atrophy (PMA), or individuals with a suspected neurodegenerative dementia and/or movement disorder of unknown etiology will be considered for enrollment 2. Family Members of individuals who meet the criteria of group 1, who are people who may or may not be at risk for a similar neurodegenerative disease, who may or may not be symptomatic, and who may or may not have known or unknown genetic risk. 3. People with no known neurological disease who will provide control data. Exclusion Criteria: 1. Anyone who is under the age of 18. 2. Anyone with a condition or in a situation which, in the investigator's opinion, could confound the study findings or may interfere significantly with a person's participation, including but not limited to neurological, psychological, and other medical conditions (such as cardiac, neurosurgical, infectious conditions).

ClinicalTrials.gov record NCT07798700

Biofluid Research on Age-Related or Inherited Neurodegeneration

Record copied from ClinicalTrials.gov: Oct 10, 2026AI summaries generated: Sep 5, 2026

Biofluid Research on Age-Related or Inherited Neurodegeneration (BRAIN)

About this page. This page shows the study's official ClinicalTrials.gov record ↗, with added help to make it easier to understand. We explain medical terms, highlight key details in plain language, and suggest questions you may want to ask the study team.

The record is periodically copied from ClinicalTrials.gov and may lag behind changes. AI summaries are checked by software, not a clinician.Read moreShow less

The official record is written by the study sponsor and published on ClinicalTrials.gov. It may not always reflect the latest changes. Before making any decisions, please confirm important information with the study team and your own healthcare team.

Where you see "AI summary", AI was used to create a plain-language explanation and software checked it against the source. It has not been reviewed by a clinician, so it may contain mistakes or leave out important details.

StatusRecruitingThe study is currently enrolling participants. Only the study team can say whether a particular person can join.

Study typeObservationalA study in which researchers do not assign participants to a treatment or other intervention. They observe or measure what happens, which may include study visits, tests, questionnaires or a review of medical records.

Healthy volunteersAcceptedPeople who do not have the condition being studied who are allowed to take part. Some studies include both people with the condition and healthy volunteers; others may enrol only healthy volunteers.

Age18 years old and older

SexAll

LocationUnited States

AI summaryWhat this study is about, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

This observational registry collects and stores blood samples, DNA/RNA, family history, and demographic information to support research into neurodegenerative diseases. It includes adults with age-related or inherited neurodegenerative conditions, their family members, and people without known neurological disease as controls. Participants are followed from enrollment until death, withdrawal, end of funding, or for up to 600 months.

What it is studying. The study is building and maintaining a repository of biological samples and linked data to enable research into the molecular and genetic basis and risk factors of age-related and inherited neurodegenerative diseases.

What the researchers hope to learn. Scientific goals: contribute to and sustain a repository of biological samples and data; collect and bank data and biospecimens to support research; include people who cannot join other protocols; extend analysis, maintenance, and sharing of existing data and samples to advance understanding of the molecular and genetic drivers and risk factors of neurodegenerative diseases.

What this study is about

The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.

The aim of this study is to contribute to and continue to sustain a repository of blood samples, nucleic acid (DNA and/or RNA) samples, family history information, and other demographic information from individuals with age-related neurodegenerative conditions, or their family members who may or may not be at risk for similar conditions. This study will continue to further expand research into the molecular and genetic basis of these diseases and their risk factors.

Eligibility

The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.

Inclusion criteria

People with a clinical diagnosis of a neurodegenerative disease including, but not limited to Alzheimer's disease (AD), Parkinson's disease (PD), Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP), primary progressive aphasia (PPA), limbic-predominant age-related TDP-43 encephalopathy (LATE), corticobasal syndrome (CBS), posterior cortical atrophy (PCA), primary lateral sclerosis (PLS), primary muscular atrophy (PMA), or individuals with a suspected neurodegenerative dementia and/or movement disorder of unknown etiology will be considered for enrollment
Family Members of individuals who meet the criteria of group 1, who are people who may or may not be at risk for a similar neurodegenerative disease, who may or may not be symptomatic, and who may or may not have known or unknown genetic risk.
People with no known neurological disease who will provide control data.

Exclusion criteria

Anyone who is under the age of 18.
Anyone with a condition or in a situation which, in the investigator's opinion, could confound the study findings or may interfere significantly with a person's participation, including but not limited to neurological, psychological, and other medical conditions (such as cardiac, neurosurgical, infectious conditions).

Study description and what participation involves

The registry record has no detailed description beyond the summary above.

AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

Participants provide blood and nucleic acid (DNA and/or RNA) samples and give family history and other demographic or health information. Data and biospecimens are collected and stored in a repository and may be shared with collaborating biobanks or used in other research; participants may be co‑enrolled in external protocols. Participants are followed long term—from enrollment until death, withdrawal, end of funding, or up to 600 months. The registry record does not list specific visit schedules or other procedures.

How the study is structured. This is an observational cohort registry (a natural history-type study). Participants provide blood and nucleic acid (DNA and/or RNA) samples and family and demographic information; these data and samples are stored locally and may be shared with collaborating biobanks. Participants are followed over time and may be co-enrolled in other approved research protocols; no experimental treatments are assigned.

Questions you could ask

These questions are suggestions for a conversation with the study team or your own clinician, not advice.

This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
The listed sites are in United States. Is any of them reachable for me, and does the study help with travel?
Which of the eligibility criteria would need to be checked with tests before I could join?

More on progressive supranuclear palsy

Clinical trials45 trials listed for progressive supranuclear palsyEvery trial the registry lists for progressive supranuclear palsy, with recruitment status, phase and sites, updated from ClinicalTrials.gov.See all trials →Research updatesWhat changed in progressive supranuclear palsy researchLatest monthly update: September 2026. Includes: PSP vs Parkinsons. New research summarized each month in plain language, with links to every source paper.Read the latest update →

Important dates

Study start: Dec 12, 2025
Primary completion: Jan 1, 2070 (estimated)
Study completion: Jan 1, 2070 (estimated)
Target enrollment: 1000 participants (estimated)
Last updated on registry: Sep 1, 2026
Data verified: Oct 10, 2026

Sponsor and research team

The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.

Lead sponsor: University of Pennsylvania
Principal investigator: Corey McMillan, PhD, Associate Professor of Neurology
University of Pennsylvania
Collaborators: University of Pennsylvania Institute on Aging
National Institute on Aging (NIA)
National Institute of Neurological Disorders and Stroke (NINDS)

Central study contact

If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.

Cara Joyce, MPH 📞 267-271-0740 ✉ cara.joyce@pennmedicine.upenn.edu
Emily Xie 📞 16109553114 ✉ emily.xie@pennmedicine.upenn.edu

Participating sites (1)

University of PennsylvaniaRecruiting
Philadelphia, Pennsylvania, 19104 · United States
- Cara Joyce, MPH · 267-271-0740 · cara.joyce@pennmedicine.upenn.edu
- Emily Xie · emily.xie@pennmedicine.upenn.edu
- Corey McMillan, PhD

Terms used on this page · explanations by MedicalUpdates.ai

enrollment: The number of participants a study plans to include, or has included. 'Estimated' means the planned number; 'actual' means the number who joined.
Inclusion Criteria: The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
Exclusion Criteria: The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.

The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.

← Back to clinical trials